August 2, 2023
HEALTH CANADA HAS ISSUED A NOTICE OF COMPLIANCE WITH CONDITIONS (NOC/C) FOR TECVAYLI™ (TECLISTAMAB INJECTION)
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued a Notice of Compliance with conditions (NOC/c) for TECVAYLI™ (teclistamab injection) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. Teclistamab is a bispecific antibody that targets the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen (BCMA) expressed on the surface of malignant multiple myeloma cells.